Despite positive clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial resistance from pharmacy benefit managers. Such organizations are https://nellxyqk952481.csublogs.com/49970411/the-drug-faces-is-encountering-pbm-hurdles-a-look-of-reimbursement-fights